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ABSTRACT
Introduction Knee osteoarthritis (OA) is a prevalent and 
disabling musculoskeletal condition. Biomechanical factors 
may play a key role in the aetiology of knee OA, therefore, 
a broad class of interventions involves the application 
or wear of devices designed to mechanically support 
knees with OA. These include gait aids, bracing, taping, 
orthotics and footwear. The literature regarding efficacy 
of mechanical interventions has been conflicting or 
inconclusive, and this may be because certain subgroups 
with knee OA respond better to mechanical interventions. 
Our primary aim is to identify subgroups with knee OA who 
respond favourably to mechanical interventions.
Methods and analysis We will conduct a systematic 
review to identify randomised clinical trials of any 
mechanical intervention for the treatment of knee OA. 
We will invite lead authors of eligible studies to share 
individual participant data (IPD). We will perform an IPD 
meta- analysis for each type of mechanical intervention 
to evaluate efficacy, with our main outcome being pain. 
Where IPD are not available, this will be achieved using 
aggregate data. We will then evaluate five potential 
treatment effect modifiers using a two- stage approach. If 
data permit, we will also evaluate whether biomechanics 
mediate the effects of mechanical interventions on pain in 
knee OA.
Ethics and dissemination No new data will be collected 
in this study. We will adhere to institutional, national 
and international regulations regarding the secure and 
confidential sharing of IPD, addressing ethics as indicated. 
We will disseminate findings via international conferences, 
open- source publication in peer- reviewed journals and 
summaries posted on websites serving the public and 
clinicians.
PROSPERO registration number CRD42020155466.
INTRODUCTION
Knee osteoarthritis (OA) is a chronic muscu-
loskeletal condition that affects approxi-
mately 24% of older adults.1 It is associated 
with substantial pain, loss of function and 
reduced quality of life.2 There are currently 
no known disease- modifying treatment 
approaches available for knee OA. Current 
guidelines recommend a core approach 
of exercise, education and dietary weight 
management if appropriate.3 Adjunct 
interventions recommended for symptom 
management include pharmaceuticals such 
as non- steroidal anti- inflammatories, but also 
certain non- pharmacological interventions 
such as gait aids.3 At the end stages of knee 
OA, when pain and disability become severe 
enough, knee arthroplasty is often under-
taken. However, approximately 20% of indi-
viduals who undergo knee arthroplasty report 
not being satisfied following surgery.4–6 With 
no effective disease- modifying treatment 
options, individuals often spend decades 
living with pain and disability.7 It is thus clini-
cally imperative to identify interventions that 
can contribute to symptom management in 
individuals living with knee OA.
Strengths and limitations of this study
 ► We designed our protocol in collaboration with the 
osteoarthritis Trial Bank, an internationally rec-
ognised organisation with considerable individual 
participant data (IPD) experience, including estab-
lished procedures for navigating the safe transfer 
and storage of IPD.
 ► IPD meta- analyses of randomised clinical trials 
enhance the ability to handle participant- level and 
study- level confounding, and increases the power 
to identify responder subgroups and mechanisms 
underlying treatment effects.
 ► A key limitation to undertaking IPD analyses re-
lates to overcoming data- sharing hurdles, and the 
achievement of our aims will in part depend on 
the ability to successfully obtain IPD from eligible 
studies.
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Biomechanical factors, such as bony malalignment 
or poor movement patterns, may play a key role in the 
aetiology of knee OA by contributing to abnormal forces 
across affected joints.8 Therefore, one broad class of 
interventions for knee OA involves application, or wear, 
of devices aimed at presumably improving an individual’s 
biomechanics to reduce joint forces, improve symptoms 
and potentially modify the disease trajectory. Such inter-
ventions include gait aids such as canes, but also bracing, 
taping, orthotics and footwear, and they can easily serve 
as adjuncts to the current recommended core exercise- 
focused programmes.3 9 10 This may be particularly 
relevant in individuals with certain biomechanical anom-
alies—such as frontal plane knee malalignment—because 
these individuals may be less likely to respond favourably 
to exercise.11 These commonly prescribed treatments are 
relatively inexpensive, less invasive and have fewer side 
effects compared with other medical approaches such as 
intra- articular injections, oral medications or surgery.12–14 
Systematic reviews suggest some such mechanical inter-
ventions (eg, knee braces) may improve pain, though 
results have been conflicting or inconclusive regarding 
other outcomes or in other mechanical interventions.12–21
One possible reason for conflicting results is that knee 
OA represents a heterogeneous disease and certain 
subgroups with knee OA may respond better to mechan-
ical interventions than others.22–24 For example, lateral 
wedge insoles and insoles with subtalar strapping may 
be more effective in individuals with varus knee align-
ment,13 14 17 21 while medial wedge insoles may be more 
effective in individuals with valgus knee alignment.14 
Including both of these groups of individuals in the same 
study could mask true treatment effects. While subgroup 
analyses within such a trial may successfully identify a 
‘responder’ subgroup, most trials are not powered for 
such secondary analyses, and evaluating multiple possible 
subgroup characteristics further increases the likelihood 
of spurious findings.25–27 Confirming the existence of such 
‘responder’ subgroups could lead to identifying effective 
targeted biomechanical interventions in knee OA.
In addition to subgroup characteristics, another 
possible reason for conflicting results is the mechanism by 
which such interventions impart their effect. If the effect 
of mechanical interventions is mediated by a change in 
some biomechanical feature, then it may be that different 
types (eg, brace vs tape), design or dose of intervention 
will confer different outcomes via differing influence on 
the mediating feature.28 Confirming the mediating role 
that biomechanics may play in mechanical interventions 
could help to optimise the design and application of 
mechanical interventions.
Several systematic reviews have evaluated the efficacy of 
mechanical interventions in knee OA, however, very little 
attention has been given to treatment effect modifiers or 
mediation analyses.12–21 Moreover, to our knowledge, no 
study on this topic has yet to pool individual participant 
data (IPD) across studies. An IPD meta- analysis evaluates 
raw units of data rather than aggregate study- level data, 
and is thus a more robust approach to evaluating treat-
ment effect modifiers and mediators.29 30 Compared with 
traditional study- level meta- analyses, IPD meta- analyses of 
randomised controlled trials (RCTs) enhances the ability 
to handle participant- level and study- level confounding, 
and increases the power to identify responder subgroups 
and mechanisms underlying treatment effects.30 The 
results using such an approach may, therefore, be more 
reliable and generalisable.30
Despite the growing recognition of the ethical and 
scientific importance of data sharing and scientific trans-
parency, one of the biggest challenges in undertaking IPD 
analyses relates to overcoming data- sharing hurdles.31–33 
Barriers range from successfully reaching original study 
authors; willingness or ability of authors to share data; 
and international ethics and regulations issues.31–33 The 
OA Trial Bank is an internationally recognised organi-
sation that was established in 2010 and has developed 
procedures for navigating these barriers, including safely 
sharing, handling and storing IPD data from RCTs.34 The 
OA Trial Bank steering committee supports and approves 
all projects, including providing input on research ques-
tions and study methods. This is, therefore, the ideal 
organisation in the field of clinical OA research to collabo-
rate with in successfully conducting an IPD meta- analysis.
AIMS
We aim to conduct a systematic review and IPD meta- 
analysis of RCTs, under the guidance of the OA Trial 
Bank, to evaluate the efficacy of mechanical interven-
tions (ie, bracing, taping, orthoses, footwear or canes) in 
managing knee OA symptoms. Our primary aim is to iden-
tify subgroups of individuals with knee OA who respond 
favourably to mechanical interventions. Our secondary 
aim is to evaluate the effect of biomechanics as a medi-
ator between mechanical interventions and symptoms.
METHODS AND ANALYSES
The OA Trial Bank steering committee approved a 
summary of this study protocol prior to preparing the 
full study protocol,34 and we published a basic study 
protocol with the International Prospective Register of 
Systematic Reviews.35 The current detailed protocol has 
been written in accordance with the Preferred Reporting 
Items for Systematic Reviews and Meta- Analyses Protocols 
(PRISMA)36 37 statement and PRISMA IPD (PRISMA- IPD) 
guidelines.29 In collaboration with the OA Trial Bank, 
we will use methods described previously to guide the 
transfer and use of IPD,38–40 updated recently to adhere 
to current European data- sharing regulations.41
We will search for relevant studies in five databases: 
MEDLINE, Embase, CINAHL, CENTRAL and Web of 
Science, with dates from inception to search date. An 
initial search was completed 21 August 2019, and we 
will update this search prior to beginning data analyses. 
We will develop a search strategy in collaboration with 
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an Erasmus MC librarian, using key words and medical 
subject headers, and adapting the syntax to the respec-
tive indexing vocabularies of each database (see online 
supplemental appendix 1).
We will identify studies that meet the following eligi-
bility criteria:
Participants
Adults (18 years or older) with knee OA (tibiofemoral or 
patellofemoral), diagnosed using any common method 
(eg, radiographs, MRI, clinical criteria, diagnosis by a 
healthcare professional). We will exclude studies where 
OA is determined by self- report alone. We will include 
post- traumatic OA, in particular knees with OA secondary 
to anterior cruciate ligament injury, regardless of whether 
or not they were previously reconstructed or repaired. We 
will, however, exclude knees with non- traumatic OA that 
have undergone major surgical procedures such as tibial 
osteotomy or total knee arthroplasty. We will exclude 
rheumatoid or other inflammatory arthropathies. If a 
study contains a subgroup of participants that meet our 
inclusion criteria, we will include that study if IPD data 
are retrieved, or if subgroup analyses are reported in the 
original publication.
Interventions
Any intervention involving use or wear of mechanical 
devices (eg, bracing, taping, orthotics, footwear, cane) 
that is evaluated after more than 1 day or application 
of wear/use. We will include studies that combine these 
interventions with exercise or education/advice.
Comparison
Any non- surgical treatment (eg, placebo, usual care, any 
other intervention that does not involve surgery), waiting 
list or no treatment.
Outcomes
Our main outcome will be pain at the end of the study- 
specific primary duration of treatment. Treatment dura-
tion will be categorised as short term (<4 weeks), medium 
term (4–12 weeks) and long term (>3 months). Outcome 
measures will also be extracted at additional time points 
during treatment. We will not extract outcomes at any 
time points that are measured after discontinuation of 
treatment. Secondary outcomes will include function, 
quality of life, global perceived change, OA feature 
severity, biomechanics and adverse events.
Study design
We will include peer- reviewed RCTs (or quasi- RCTs). 
We will exclude any other study design (eg, non- RCTs, 
prestudy and poststudy designs, observational studies). 
We will also exclude RCTs that only measure the acute 
effects of a single application of treatment.
Languages
English, Dutch, German, French
Titles and abstracts will be initially imported into 
EndNote X9 (Clarivate Analytics) for deduplication, 
and then imported into Covidence for screening.42 Two 
independent reviewers (EMM and MC) will screen titles 
and abstracts of all studies identified through this search 
strategy.43 A third reviewer (MvM) will be consulted in 
the event of unresolved disagreements. Following the 
initial screening, two reviewers (EMM and MC) will inde-
pendently review full text manuscripts to identify studies 
for inclusion in this review. A third reviewer (MvM) will 
again be consulted in the event of disagreements. We will 
review reference lists of included studies and relevant 
reviews for additional eligible studies.
For all included studies, we will contact the corre-
sponding author by email. If a current email address 
cannot be found or the author does not respond (up to 
three attempts), we will attempt to reach them by other 
means (eg, phone, post, contact institution). Where 
IPD are available and authors or institutions are willing 
to share data, a data delivery agreement will be signed 
by both parties. Where local ethics regulations require 
it, ethics approval will be sought prior to sharing data. 
Pseudonymised or anonymised data sets (all formats are 
acceptable, eg, SPSS, Excel) and related data dictionaries 
will then be transferred and stored securely on a data-
base at Erasmus MC, for use only as agreed on in the data 
delivery agreement. One original study investigator (first 
or senior author, at the discretion of the data owner) 
will be invited to be a coauthor of the project if they are 
willing to assume responsibilities that meet authorship 
guidelines.
We will convert all data sets to a common format, 
combine data sets with a new variable identifying original 
trial and harmonise variables. Data checking will include 
evaluating baseline characteristics and results of compar-
isons for our main outcomes against results reported in 
original publications. We will also check for balancing 
of baseline participant characteristics in each treatment 
arm, and evaluate the extent to which all randomised 
participants in the IPD datasets have been included in 
study analyses. Authors will be consulted in the case of 
any inconsistencies or discrepancies. In cases where 
discrepancies cannot be resolved, we will (on a case by 
case basis) either conduct a sensitivity analysis with that 
study removed, or we will exclude the study from our 
analysis altogether.
Data extraction
Two independent investigators will extract data from 
all included published studies. From each study, we will 
extract the following data: country of study; funding 
source; study design; sample size; target population; 
inclusion/exclusion criteria; participant characteristics 
(age, sex, BMI, history of injury or surgery, comorbidities, 
psychosocial profile, metabolic profile, physical activity/
fitness, lifestyle factors, medication use); type, dose and 
context of intervention (including compliance, cointer-
ventions, protocol deviations, adverse events, drop- out 
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or withdrawal details); OA characteristics (compart-
ment involvement, prevalence, severity, tissues involved), 
including pre–post if available; and pain, function, 
quality of life and biomechanics (eg, proprioception, 
knee alignment, strength, kinematics, kinetics) pre–
post as available. Global perceived change will also be 
extracted as available. For all patient- reported outcomes, 
we will extract recall period in addition to the outcome. 
For all outcome measures, notably biomechanics, we will 
also extract whether scores and measures are taken with 
respect to the device applied/worn or removed. Where 
IPD are available, we will conduct all analyses using IPD 
instead of aggregate data, following data consistency 
checks described above.
Risk of Bias
Two coauthors will independently evaluate risk of bias 
(ROB) for each included study using the Cochrane 
ROB tool V.2,44 and disagreements will be resolved by a 
third investigator. The Cochrane ROB V.2 considers five 
domains of possible bias: randomisation; deviations from 
intended interventions; missing outcome data; measure-
ment of the outcome and selection of the reported results. 
For each domain, ROB is rated as low, some concerns or 
high. Both the original publications and IPD datasets 
will be used for evaluating ROB. The overall study will be 
considered to be of low ROB if all five domains are rated 
as low ROB, and high overall ROB if at least one domain 
is rated as high ROB or if some concerns are identified in 
multiple domains. We will consult original authors in the 
event of inadequate reporting or inconsistencies.
Statistical analyses
We will conduct an IPD meta- analysis of short term (<4 
weeks), medium term (4–12 weeks) and long term (>3 
months) effects of mechanical treatments (alone or 
in combination with exercise or education/advice) in 
comparison to other non- surgical treatments, sham, wait-
list or usual care.
Where within- study missing data are sparse (less than 
5%), we will assume data are missing completely at random 
and we will conduct complete case analyses, given the trivial 
loss of power and negligible implications on bias.45 Where 
higher proportions of data are missing within a study, we will 
conduct within- study multiple imputation.45 46 In cases where 
a variable was not collected in a given study, we will exclude 
that study from the relevant analyses.
Treatment efficacy
To evaluate treatment efficacy, we will employ a two- step 
meta- analysis, first analysing each trial separately, and 
then pooling results across trials.30 38 47 In step 1, within 
each trial, we will evaluate the effect of assigned interven-
tion by intention to treat, regardless of method used in 
the original study. We anticipate that our main outcome, 
pain, will be evaluated differently across studies. To 
navigate this, we will evaluate the pain- related outcome 
from each study that ranks highest on the recommended 
hierarchy of pain- related outcomes to be used for meta- 
analyses48 (see table 1). For each available time point 
(short term, medium term and long- term), we will fit an 
analysis of covariance (ANCOVA) model to obtain the 
treatment effect estimate, including baseline pain as a 
covariate.49 We will report effect sizes from the ANCOVA 
model and their respective 95% CI. If study heterogeneity 
prevents us from harmonising pain data, then we will 
navigate this using a statistical approach based on avail-
able data. This will likely involve transforming data into 
standardised means differences or applying proportion 
of maximum scaling methods.50
In studies where we are unable to obtain IPD, we will 
extract aggregate data from published manuscripts as 
they are reported, for example, based on final scores or 
change scores.51 Similar models will be performed for 
secondary outcomes as data permit. In cases of dichot-
omous outcomes, we will perform binary modelling and 
report effect sizes as relative risk (RR, 95% CI).
In step 2, we will perform random effects meta- analysis 
employing restricted maximum likelihood.52 We will 
perform separate meta- analyses for each type of inter-
vention (eg, braces, taping).30 47 53 We will report study 
heterogeneity as I2 and τ2 .54 55 In cases of notable hetero-
geneity (I2 >50%),55 we will consider possible sources 
such as device design, treatment duration, comparison 
treatment, treatment adherence or study quality. We will 
then consider performing meta- regression, subgroup 
analysis or sensitivity analyses to explain or account for 
these potential sources of heterogeneity. We will pool 
results of studies both with and without IPD data after 
verifying that effect sizes of IPD studies do not differ from 
non- IPD studies.30 51
In addition to a two- step meta- analysis, we will also 
perform a one- step meta- analysis as a sensitivity analysis. 
Table 1 Hierarchy of pain- related outcomes proposed by 
Jüni et al48
Rank Pain outcome
Highest Global pain score (eg, NRS, VAS)
  Pain on walking (same as one but task- specific)
  WOMAC pain subscale59
  Other composite pain scores (eg, KOOS Pain)60
  Pain on activities other than walking (eg, stair 
climbing)
  WOMAC global score (all three subscales 
combined)
  Lequesne osteoarthritis index global score61
  Other algo- functional composite scores
  Patient’s global assessment
Lowest Physician’s global assessment
KOOS, Knee injury and Osteoarthritis Outcome Score; NRS, 
Numeric Rating Score; VAS, Visual Analogue Scale; WOMAC, 
Western Ontario McMaster University Osteoarthritis Index.
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In a one- step meta- analysis, all IPD datasets are harmon-
ised into one large dataset and analysed together, with the 
addition of a covariate indicating original trial.
Within studies for which we have IPD and that report 
adherence to treatment, we will evaluate correlations 
between adherence and treatment effects. Where IPD are 
not available, we will extract aggregate data if reported. 
While we expect clinical and statistical heterogeneity to 
prevent meaningful meta- analysis of these data, we will 
pool data where possible.
Treatment effect-modifier analyses
We will conduct treatment effect- modifier analyses to iden-
tify subgroups of individuals with knee OA who respond to 
various mechanical interventions.38 We have proposed several 
subgroup characteristics that we hypothesise may modify the 
effect of mechanical interventions on our main outcome, 
based on expert opinion. These proposed subgroups include 
the following baseline characteristics: (1) mild vs severe OA 
(more severe joint space narrowing is associated with joint 
malalignment which may respond differently to mechanical 
interventions); (2) location of OA, specifically tibiofemoral 
versus patellofemoral OA, medial versus lateral tibiofemoral 
OA, or medial versus lateral patellofemoral OA (location of 
cartilage damage may be associated with differing joint align-
ment or source of symptoms); (3) varus versus valgus knee 
alignment (may be associated with different localised joint 
forces); (4) obese versus non- obese (may confer different 
amounts of mechanical stress) and (5) post- traumatic versus 
non- traumatic OA (possible different biomechanical anom-
alies). Where feasible, we will apply a two- stage approach, 
whereby we first investigate within- trial interactions within 
each study using IPD data, then pool results across trials.27 53 
This approach separates within- trial variation from across- 
trial variation, thus reducing the risk of ecological bias by 
analysing the effect of interest for individuals rather than 
groups of individuals.27 We will conduct all treatment effect- 
modifier analyses in IPD data only.53
Mediation analyses
We hypothesise that biomechanical factors may mediate 
the effect of these interventions (eg, kinematics, kinetics, 
proprioception, hypermobility) by reducing or normal-
ising joint forces, which in turn reduces pain. If possible, 
we will conduct mediation analyses to evaluate this 
hypothesis.38 We acknowledge that it is rare for studies 
to evaluate biomechanical variables both before- and- after 
treatment, so undertaking this analysis will depend on 
whether there are sufficient data available in included 
studies. If such an analysis is possible, we will employ a 
single mediator model to evaluate the proportion of the 
total effect of the intervention on pain that is mediated by 
a change in biomechanics.56
We will conduct funnel plot analyses where there are at 
least ten studies for a given intervention, to consider the 
possible effects of small sample size or publication bias.57 
We will summarise the overall level of evidence for each 
category of intervention using the GRADE approach.58
All analyses will be performed using Stata V.15.1 
(StataCorp).
Patient and public involvement
Patients and the public were not directly involved in the 
design of this study protocol. The OA Trial Bank advisory 
board includes patient members who provide overall 
input to the OA Trial Bank Steering Committee activities. 
We will solicit patient involvement through the OA Trial 
Bank advisory board and also through our institutional 
patient advisors ( www. arthrosegezond. nl) for input in the 
analysis and interpretation of our study results, and to 
inform and guide dissemination of our study results.
ETHICS AND DISSEMINATION
No new data will be collected, so de novo ethics approval 
is not required for our study. The OA Trial Bank has estab-
lished protocols in place to guide the confidential and 
secure transfer and use of pseudonymised IPD38–40 that 
adheres to current European data- sharing regulations.41 
We will collaborate with data deliverers to also adhere to 
relevant institutional, national or international regula-
tions regarding data sharing and ethics. We will store all 
IPD datasets on a secure driver in accordance with OA 
Trial Bank procedures. We will disseminate findings via 
international conferences, open- source publication in 
peer- reviewed journals and summaries posted on websites 
serving the public and clinicians.
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